PEPS
MCID: EPL050
MIFTS: 26

Epilepsy, Partial, with Pericentral Spikes (PEPS)

Aliases & Classifications for Epilepsy, Partial, with Pericentral Spikes

MalaCards integrated aliases for Epilepsy, Partial, with Pericentral Spikes:

Name: Epilepsy, Partial, with Pericentral Spikes 57 13 71
Peps 57
Epps 57

External Ids:

OMIM® 57 607221
UMLS 71 C1846609

Summaries for Epilepsy, Partial, with Pericentral Spikes

MalaCards based summary : Epilepsy, Partial, with Pericentral Spikes, also known as peps, is related to chlamydia pneumonia and chlamydia. An important gene associated with Epilepsy, Partial, with Pericentral Spikes is EPPS (Epilepsy, Partial, With Pericentral Spikes). The drugs Acetylcysteine and Indomethacin have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and skin.

More information from OMIM: 607221

Related Diseases for Epilepsy, Partial, with Pericentral Spikes

Diseases related to Epilepsy, Partial, with Pericentral Spikes via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 20)
# Related Disease Score Top Affiliating Genes
1 chlamydia pneumonia 10.2
2 chlamydia 10.2
3 cerebrovascular disease 10.2
4 personality disorder 10.1
5 transient cerebral ischemia 10.1
6 paroxysmal extreme pain disorder 10.0
7 vascular disease 10.0
8 brain injury 10.0
9 traumatic brain injury 10.0
10 rheumatoid arthritis 9.9
11 schizophrenia 9.9
12 neural tube defects 9.9
13 down syndrome 9.9
14 wolf-hirschhorn syndrome 9.9
15 autism spectrum disorder 9.9
16 mild cognitive impairment 9.9
17 epilepsy 9.9
18 focal epilepsy 9.9
19 arthritis 9.9
20 chronic pain 9.9

Graphical network of the top 20 diseases related to Epilepsy, Partial, with Pericentral Spikes:



Diseases related to Epilepsy, Partial, with Pericentral Spikes

Symptoms & Phenotypes for Epilepsy, Partial, with Pericentral Spikes

Clinical features from OMIM®:

607221 (Updated 05-Mar-2021)

Drugs & Therapeutics for Epilepsy, Partial, with Pericentral Spikes

Drugs for Epilepsy, Partial, with Pericentral Spikes (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
3
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
6 Respiratory System Agents Phase 4
7 Expectorants Phase 4
8 N-monoacetylcystine Phase 4
9 Antidotes Phase 4
10 Analgesics Phase 4
11 Immunoglobulins Phase 4
12 Antibodies Phase 4
13 Anti-Inflammatory Agents Phase 4
14 Antibodies, Blocking Phase 4
15 Analgesics, Non-Narcotic Phase 4
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4
17 Cyclooxygenase Inhibitors Phase 4
18 Tocolytic Agents Phase 4
19 Anti-Infective Agents Phase 4
20 Anti-Bacterial Agents Phase 4
21 Antiparasitic Agents Phase 4
22 Antiprotozoal Agents Phase 4
23 Antimalarials Phase 4
24 Gastrointestinal Agents Phase 4
25 Dopamine Agents Phase 4
26 Dopamine Antagonists Phase 4
27 Antiemetics Phase 4
28 Neurotransmitter Agents Phase 4
29
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
30
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
31
Afamelanotide Approved, Investigational Phase 3 75921-69-6
32
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
33
Rifampicin Approved Phase 3 13292-46-1 5458213 5381226
34
Emtricitabine Approved, Investigational Phase 3 143491-57-0 60877
35
Hydroxychloroquine Approved Phase 3 118-42-3 3652
36
Vitamin C Approved, Nutraceutical Phase 2, Phase 3 50-81-7 5785 54670067
37
Tenofovir Experimental, Investigational Phase 3 147127-20-6 464205
38 Antifungal Agents Phase 3
39 Cytochrome P-450 Enzyme Inhibitors Phase 3
40 Hormone Antagonists Phase 3
41 Hormones Phase 3
42 Anti-Infective Agents, Local Phase 3
43 Cytochrome P-450 CYP3A Inhibitors Phase 3
44 Protective Agents Phase 2, Phase 3
45 Antioxidants Phase 2, Phase 3
46 Vasoconstrictor Agents Phase 2, Phase 3
47 Dermatologic Agents Phase 3
48 Nutrients Phase 2, Phase 3
49 Micronutrients Phase 2, Phase 3
50 Trace Elements Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 145)
# Name Status NCT ID Phase Drugs
1 Comparative Evaluation of Standard Prophylaxis Versus Divided-dose NSAIDs or Hybrid NSAID and N-acetylcysteine Therapy for the Prevention of Post-ERCP Pancreatitis Unknown status NCT03708458 Phase 4 indomethacin suppository;N-acetylcysteine (NAC)
2 Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP) Completed NCT02111707 Phase 4 Rectal indomethacin 100mg one time before or after ERCP
3 Antepartum Study on Use of Interpersonal Psychotherapy at 3 New York City Sites Completed NCT00251043 Phase 4
4 A Phase IV, Open Label, Single-center Extension Study, to Evaluate the Long-term Persistence of Immune Responses After Post-exposure Prophylaxis With Purified Chicken-embryo Cell Rabies Vaccine in Chinese Children Completed NCT02991872 Phase 4
5 Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men Recruiting NCT03980223 Phase 4 Doxycycline Hyclate Delayed-Release 200 mg
6 PEP uP Protocol (Enhanced Protein-Energy Provision Via the Enteral roUte Feeding Protocol) in Surgical Patients Terminated NCT02459275 Phase 4 Metoclopramide
7 A Multicenter Study to Evaluate the Effects on Charcot-Marie-Tooth Neuropathy Type 1A of a Composite Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program. Unknown status NCT01289704 Phase 2, Phase 3
8 A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis Completed NCT01641393 Phase 3 EUR-1008 25,000 Units;Kreon 25,000 Units
9 The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study. Completed NCT04480593 Phase 2, Phase 3 Brazilian Green Propolis Extract (EPP-AF)
10 A Phase III, Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP) Completed NCT04578496 Phase 3 Afamelanotide
11 Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic in Elderly People Completed NCT02818803 Phase 3 Miconazole
12 A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutanenous Bioresorbable CUV1647 Implants in Patients With Erythropoietic Protoporphyria (EPP) Completed NCT04053270 Phase 3 Afamelanotide;Placebo
13 A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP) Completed NCT00979745 Phase 3 Afamelanotide;Placebo
14 A Phase III, Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP) Completed NCT01605136 Phase 3 Afamelanotide;Placebo
15 Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study Completed NCT04328961 Phase 2, Phase 3 Hydroxychloroquine Sulfate;Ascorbic Acid
16 A Randomized, Double-Blind, Placebo-Controlled, Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00297167 Phase 3 EUR-1008 (APT-1008);Placebo;Placebo;EUR-1008 (APT-1008)
17 Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study) Completed NCT04304053 Phase 3 Treatment and prophylaxis
18 An Open-Label Study to Evaluate the Efficacy and Safety of Pancreatic Enzyme Product (PEP) Microtabs in Pediatric Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00981214 Phase 3 EUR-1008 (APT-1008)
19 A Prospective Open-label Randomized Controlled Trial Comparing Effectiveness of Aggressive Hydration Versus High-dose Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis (PEP) Completed NCT03629600 Phase 2, Phase 3 Lactated Ringer;Rectal Form Indometacin
20 Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Open Level Control Clinical Trial Completed NCT04408456 Phase 3 HCQ
21 A Phase III Randomized Study Comparing the Effects of a Personalized Exercise Program (PEP) Against No Intervention in Patients With Stage I-IIIa Primary Non-Small Cell Lung Cancer or Secondary Lung Cancer Undergoing Surgical Resection Recruiting NCT03306992 Phase 3
22 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria Recruiting NCT04402489 Phase 3 Placebo;MT-7117 Low Dose;MT-7117 High Dose
23 Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial Recruiting NCT04318444 Phase 2, Phase 3 Hydroxychloroquine;Placebo oral tablet
24 MET-COVID Trial - Metformin for Outpatient Treatment and Post-exposure Prophylaxis (PEP) of COVID-19 Recruiting NCT04510194 Phase 2, Phase 3 Metformin;Placebo
25 A Phase III Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Category III Rabies Exposure Risks Recruiting NCT04644484 Phase 3
26 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Recruiting NCT03662022 Phase 3 Rifampicin
27 Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) Not yet recruiting NCT04597424 Phase 3 Experimental: doxycycline
28 Post Exposure Prophylaxis (PEP) in Healthcare Workers Exposed to COVID-19 Patients: A Double-blind Randomized Clinical Trial Not yet recruiting NCT04437693 Phase 2, Phase 3 Hydroxychloroquine
29 Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada) Terminated NCT04421664 Phase 3 Hydroxychloroquine;Placebo oral tablet
30 Randomized Clinical Trial of a Mucoadhesive Gel Containing EPP-AF in Patients Diagnosed With Vulvovaginal Candidiasis Unknown status NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
31 A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy. Unknown status NCT00895466 Phase 1, Phase 2
32 Effects of Deep Breathing Exercises Two Months After Cardiac Surgery Completed NCT01282671 Phase 2
33 A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria Completed NCT03520036 Phase 2 MT-7117 low dose;MT-7117 high dose;Placebo
34 A Phase II, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP) Completed NCT01097044 Phase 2 Afamelanotide;Placebo
35 A Randomized Phase II Trial Comparing Two Doses of Pulsed Erlotinib Prechemotherapy (PEP-C) in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00287989 Phase 2 Carboplatin;erlotinib hydrochloride;Paclitaxel;erlotinib hydrochloride
36 Personalized Exercise Programme (PEP) I: Physician Referral Approach to Increasing Awareness and Sustainability of Physical Activity for Overweight Adults With Mobility Limitations. Completed NCT00164515 Phase 2
37 Respiratory Muscle Strength, Functional Capacity and Subjective Outcome - Effects of Inspiratory Muscle Training After Lung Cancer Surgery, a Randomized Controlled Trial Completed NCT01793155 Phase 2
38 Effects of Green Propolis Extract (EPP-AF) on Inflammation in Hemodialysis Patients: a Randomized Cross-over Trial. Recruiting NCT04072341 Phase 1, Phase 2 Propolis Period (Green Propolis 250mg/day)
39 A Pilot Study of the Safety, Tolerability, Feasibility and Efficacy of Anti-PD-1 or Anti-PD-L1 in Combination With a Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac) Recruiting NCT03715985 Phase 1, Phase 2 EVAX-01-CAF09b
40 Optimizing the Delivery of HIV Post-exposure Prophylaxis: A Randomized Controlled Trial of Text Messaging Support and Physician to Nurse Task-shifting Recruiting NCT03259698 Phase 2 nPEP
41 Clinical Study of Neoadjuvant Anti-PD-1 Drug Toripalimab Combined With Chemotherapy in the Treatment of Locally Advanced Epithelial or Mixed Tissue Malignant Pleural Mesothelioma Not yet recruiting NCT04713761 Phase 2 Toripalimab
42 Personalized Exercise for Adolescents With Diabetes Completed NCT00686283 Phase 1
43 Omega-3 Fatty Acids & Psychoeducational Psychotherapy for Childhood Depression Completed NCT01341925 Phase 1 Omega-3 Supplementation
44 Zenapax®-Activated Peptide ImmunoTherapy [ZAP IT] Completed NCT00626015 Phase 1 temozolomide
45 Omega-3 Fatty Acids & Psychoeducational Psychotherapy for Childhood Bipolar Disorder- Not Otherwise Specified Completed NCT01507753 Phase 1 Omega-3 Supplementation
46 The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma Recruiting NCT03299309 Phase 1 PEP-CMV
47 A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine and Standard Of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma Recruiting NCT04627246 Phase 1
48 Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens Active, not recruiting NCT02864368 Phase 1 5-day TMZ;21-day TMZ;Tetanus-Diphtheria booster;Tetanus Pre-Conditioning
49 A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma Active, not recruiting NCT03228537 Phase 1 Atezolizumab;Cisplatin;Pemetrexed Disodium
50 Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients With AMI (EV-AMI) Not yet recruiting NCT04327635 Phase 1 PEP in Acute Myocardial Infarction

Search NIH Clinical Center for Epilepsy, Partial, with Pericentral Spikes

Genetic Tests for Epilepsy, Partial, with Pericentral Spikes

Anatomical Context for Epilepsy, Partial, with Pericentral Spikes

MalaCards organs/tissues related to Epilepsy, Partial, with Pericentral Spikes:

40
Lung, Prostate, Skin, Spinal Cord, Skeletal Muscle, Brain, Eye

Publications for Epilepsy, Partial, with Pericentral Spikes

Articles related to Epilepsy, Partial, with Pericentral Spikes:

(show top 50) (show all 321)
# Title Authors PMID Year
1
Partial epilepsy with pericentral spikes: a new familial epilepsy syndrome with evidence for linkage to chromosome 4p15. 57
12112080 2002
2
Anti-nociceptive, anti-inflammatory and anti-arthritic activities of pregnane glycosides from the root bark of Periploca sepium Bunge. 61
32890713 2021
3
Irish English PEPS-C (2015 edition) and Learners of ESL. 61
33486498 2021
4
A meta-analysis of prosody in autism, Williams syndrome, and Down syndrome. 61
33285421 2021
5
PepS: An Innovative Microfluidic Device for Bedside Whole Blood Processing before Plasma Proteomics Analyses. 61
33319979 2021
6
The effectiveness of active surveillance measures for COVID-19 cases in Pudong New Area Shanghai, China, 2020. 61
33463732 2021
7
Temporal dynamics and ecotoxicological risk assessment of personal care products, phthalate ester plasticizers, and organophosphorus flame retardants in water from Lake Victoria, Uganda. 61
32799137 2021
8
Enhancing the Biopsychosocial Approach to Perioperative Care: A Pilot Randomized Trial of the Perioperative Pain Self-Management (PePS) Intervention. 61
33351478 2020
9
Differential activities of maize plant elicitor peptides as mediators of immune signaling and herbivore resistance. 61
33058410 2020
10
Pain-autonomic interaction: A surrogate marker of central sensitization. 61
32794307 2020
11
Projected Entangled Pair States: Fundamental Analytical and Numerical Limitations. 61
33275001 2020
12
Targeting Pyruvate Kinase PEPs Up Insulin Secretion and Improves Glucose Homeostasis. 61
33147479 2020
13
Biofilm microenvironment activated supramolecular nanoparticles for enhanced photodynamic therapy of bacterial keratitis. 61
32920078 2020
14
The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. 61
33020032 2020
15
Danger-Associated Peptide Regulates Root Growth by Promoting Protons Extrusion in an AHA2-Dependent Manner in Arabidopsis. 61
33120933 2020
16
Central sensitization of nociceptive pathways demonstrated by robot-controlled pinprick-evoked brain potentials. 61
32709556 2020
17
Rationally engineered prolyl endopeptidases from Sphingomonas capsulata with improved hydrolytic activity towards pathogenic peptides of celiac diseases. 61
32668378 2020
18
Dynamic regulation of Pep-induced immunity through post-translational control of defence transcript splicing. 61
32690890 2020
19
Pilot deep RNA sequencing of worker blood samples from Singapore printing industry for occupational risk assessment. 61
33511305 2020
20
SU(3)_{1} Chiral Spin Liquid on the Square Lattice: A View from Symmetric Projected Entangled Pair States. 61
32678656 2020
21
Pharyngo-Esophageal Perforations After Anterior Cervical Spine Surgery: Management and Outcomes. 61
32315790 2020
22
Improving the Lifestyle of Adolescents Through Peer Education and Support in Vietnam: Protocol for a Pilot Cluster Randomized Controlled Trial. 61
32589155 2020
23
Danger-Associated Peptide Regulates Root Immune Responses and Root Growth by Affecting ROS Formation in Arabidopsis. 61
32605179 2020
24
Perturbation-evoked potentials can be classified from single-trial EEG. 61
32299075 2020
25
Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort. 61
31746462 2020
26
Danger peptide signaling enhances internalization of a geminivirus symptom determinant in plant cells during infection. 61
31990035 2020
27
An Energy Optimization Strategy Based on the Perfect Conformation of Prolyl Endopeptidase for Improving Catalytic Efficiency. 61
32297517 2020
28
Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. 61
32009515 2020
29
Theoretical Study on the Reduction Mechanism of Np(VI) by Hydrazine Derivatives. 61
32310650 2020
30
Transfer posterior error probability estimation for peptide identification. 61
32366221 2020
31
Pinprick Evoked Potentials-Reliable Acquisition in Healthy Human Volunteers. 61
31216028 2020
32
Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. 61
32001078 2020
33
Galois Conjugated Tensor Fusion Categories and Nonunitary Conformal Field Theory. 61
32281849 2020
34
Isolation and identification of polysaccharides from Pythium arrhenomanes and application to strawberry fruit (Fragaria ananassa Duch.) preservation. 61
31689590 2020
35
Inhalation of printer-emitted particles impairs cardiac conduction, hemodynamics, and autonomic regulation and induces arrhythmia and electrical remodeling in rats. 61
31996220 2020
36
Detection of epistasis between ACTN3 and SNAP-25 with an insight towards gymnastic aptitude identification. 61
32866209 2020
37
Gintonin stimulates autophagic flux in primary cortical astrocytes. 61
32148391 2020
38
Methicillin-sensitive Staphylococcusaureus bacterial endarteritis associated with vascular closure device. 61
31959652 2020
39
Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling in Rat Lung, Blood, and Serum for Assessment of Laser Printer-Emitted Nanoparticle Inhalation Exposure-Induced Disease Risks. 61
31888290 2019
40
High-Coverage Targeted Lipidomics Reveals Novel Serum Lipid Predictors and Lipid Pathway Dysregulation Antecedent to Type 2 Diabetes Onset in Normoglycemic Chinese Adults. 61
31455687 2019
41
Type-II Metacaspases Mediate the Processing of Plant Elicitor Peptides in Arabidopsis. 61
31454707 2019
42
Cleave and Unleash: Metacaspases Prepare Peps for Work. 61
31272898 2019
43
The feasibility and appropriateness of a peer-to-peer, play-based intervention for improving pragmatic language in children with autism spectrum disorder. 61
30175619 2019
44
Danger-Associated Peptides Interact with PIN-Dependent Local Auxin Distribution to Inhibit Root Growth in Arabidopsis. 61
33590153 2019
45
Danger-Associated Peptides Interact with PIN-Dependent Local Auxin Distribution to Inhibit Root Growth in Arabidopsis. 61
31123046 2019
46
A systematic review and meta-analysis of bivalirudin application in peripheral endovascular procedures. 61
31230646 2019
47
One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry. 61
31103407 2019
48
An intramembrane sensory circuit monitors sortase A-mediated processing of streptococcal adhesins. 61
31064885 2019
49
Central sensitization increases the pupil dilation elicited by mechanical pinprick stimulation. 61
30785805 2019
50
Rapid, label-free genetic detection of enteropathogens in stool without genetic isolation or amplification. 61
30731348 2019

Variations for Epilepsy, Partial, with Pericentral Spikes

Expression for Epilepsy, Partial, with Pericentral Spikes

Search GEO for disease gene expression data for Epilepsy, Partial, with Pericentral Spikes.

Pathways for Epilepsy, Partial, with Pericentral Spikes

GO Terms for Epilepsy, Partial, with Pericentral Spikes

Sources for Epilepsy, Partial, with Pericentral Spikes

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....